Adding anlotinib to standard temozolomide-based chemoradiotherapy significantly extended PFS for newly diagnosed glioblastoma ...

Mechanistically, we identified downregulation of vascular endothelial growth factor receptor 1 (VEGFR1), which acts as a decoy receptor for VEGF, as a key mediator of the endothelial response to ...

The combination of fruquintinib (Fruzaqla), chemotherapy, and PD-1 blockade demonstrated encouraging efficacy and manageable safety in the frontline treatment of patients with HER2-negative advanced ...

Notable data include findings from the Phase 3 LEAP-002 study, which evaluated lenvatinib (LENVIMA ®), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai ...

NUTLEY, N.J., May 20, 2025 /PRNewswire/ -- Eisai announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical ...

Expert Rev Ophthalmol. 2013;8(3):227-235. The use of anti-VEGF is rapidly becoming the standard of care for retinal vascular disease. There remains some concern regarding the duration of treatment ...